Avity Investment Management Inc. Acquires 55,223 Shares of Boston Scientific Corporation $BSX

Avity Investment Management Inc. raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 34.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 217,749 shares of the medical equipment provider’s stock after buying an additional 55,223 shares during the period. Avity Investment Management Inc.’s holdings in Boston Scientific were worth $20,762,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp boosted its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the period. Synergy Asset Management LLC boosted its holdings in shares of Boston Scientific by 3,493.0% during the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after acquiring an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC grew its position in shares of Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Boston Scientific during the third quarter worth approximately $26,955,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

Wall Street Analyst Weigh In

BSX has been the subject of several research reports. Wells Fargo & Company dropped their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. TD Cowen reduced their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Oppenheimer lowered their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Finally, Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Price Performance

BSX stock opened at $69.21 on Friday. The company has a fifty day moving average price of $77.45 and a 200-day moving average price of $90.83. The company has a market capitalization of $102.86 billion, a P/E ratio of 35.68, a PEG ratio of 1.08 and a beta of 0.69. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business earned $0.70 EPS. The company’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.